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Introduction: Epidermal growth factor receptor (EGFR) mutation 
status was reported to be associated with programmed death-ligand 
1 (PD-L1) expression. However, the molecular mechanism of PD-L1 
regulation by EGFR activation and the potential clinical significance 
of blocking PD-1/PD-L1 in EGFR-mutant non–small-cell lung can-
cer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs) 
were largely unknown.
Methods: Western blot, real-time polymerase chain reaction, immu-
nofluorescence, and flow cytometry were employed to explore 
the association between PD-L1 and EGFR activation. Then, we 
used EGFR-TKIs and downstream pathways inhibitors to clarify 
the detailed signaling pathway involved in PD-L1 regulation. Cell 
apoptosis, viability, and enzyme-linked immunosorbent assay test 
were used to study the immune suppression by EGFR activation and 
immune reactivation by EGFR-TKIs and/or PD-1 blocking in tumor 
cells and human peripheral blood mononuclear cells coculture system.
Results: We found that EGFR activation by EGF stimulation, exon-
19 deletions, and L858R mutation could induce PD-L1 expression. 
EGFR activation upregulated PD-L1 through p-ERK1/2/p-c-Jun but 
not through p-AKT/p-S6 pathway. PD-L1 mediated by EGFR acti-
vation could induce the apoptosis of T cells through PD-L1/PD-1 
axis in tumor cells and peripheral blood mononuclear cells coculture 
system. Inhibiting EGFR by EGFR-TKIs could free the inhibition 
of T cells and enhance the production of interferon-γ. Synergistic 
tumor cell killing effects were not observed with EGFR-TKIs and 
anti-PD-1 antibody combination treatment in coculture system.
Conclusions: Our results imply that EGFR-TKIs could not only 
directly inhibit tumor cell viability but also indirectly enhance anti-
tumor immunity through the downregulation of PD-L1. Anti-PD-1/
PD-L1 antibodies could be an optional therapy for EGFR-TKI sensi-
tive patients, especially for EGFR-TKIs resistant NSCLC patients 
with EGFR mutation. Combination of EGFR-TKIs and anti-PD-1/
PD-L1 antibodies treatment in NSCLC is not supported by the cur-
rent study but warrant more studies to move into clinical practice.
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Lung cancer remains the leading cause of cancer-related mor-tality worldwide.1 Non–small-cell lung cancer (NSCLC) 
accounts for approximately 85% of all lung cancer cases.2 The 
epidermal growth factor receptor (EGFR) gene is one of the 
most important oncogenes in NSCLC. It was reported that up 
to 47.9% of Asian NSCLC patients harbor EGFR mutation.3 
Two major types of EGFR kinase mutations include exon-19 
deletions and L858R mutation in exon 21,4,5 which confer 
sensitivity to EGFR tyrosine kinase inhibitors (EGFR-TKIs), 
such as gefitinib and erlotinib. However, a majority of patients 
acquire resistance during treatment, and limited strategies are 
available to handle these EGFR-TKIs resistance. Novel and 
more effective therapy for NSCLC is urgently warranted.
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Currently, immunotherapies have intensively been stud-
ied. Programmed death-1 (PD-1) and its ligand PD-L1 are the 
most promising targets in immunotherapies. The interaction 
between PD-1 and PD-L1 could inhibit the proliferation and 
activation of T cells, which eventually leads to the immune 
evasion of tumor cells.6–8 Recent studies have demonstrated 
that blocking PD-1/PD-L1 pathway can enhance the endog-
enous antitumor immunity by restoring the action of T lym-
phocytes.9,10 Thus, manipulating PD-1/PD-L1 axis might be a 
promising treatment option for NSCLC.
Recently, it is reported that PD-L1 was expressed in 
19.6% to 65.3% of NSCLC,7,11–14 and that EGFR mutation 
status was associated with PD-L1 expression.15,16 More 
interestingly, PD-L1 positive patients treated with EGFR-
TKIs have higher response rate and longer time to pro-
gression (TTP) compared with PD-L1 negative patients.17 
However, the molecular mechanism of PD-L1 regulation by 
EGFR activation and the potential clinical significance of 
blocking PD-L1/PD-1 in EGFR-mutant non–small-cell lung 
cancer (NSCLC) treated with EGFR-TKIs were largely 
unknown.
The purpose of this study is to investigate which signal-
ing pathways are involved in the upregulation of PD-L1 in 
NSCLC with EGFR activation and whether blocking PD-L1/
PD-1 could be a novel treatment option in EGFR-TKIs sensi-
tive and resistant NSCLC with EGFR mutation.
MATERIALS AND METHODS
Cell Lines and Cell Culture
Human NSCLC cell lines A549, PC9, HCC827, H1975, 
H1993, and an immortalized human lung bronchial epithe-
lial cell line (Beas-2B) were purchased from the American 
Type Culture Collection. Beas-2B-CAG-EGFR-19del, 
Beas-2B-Rosa-EGFR-19del, Beas-2B-CAG-vector, and 
Beas-2B-EGFR-L858R stable cell lines were constructed 
and generously provided by Prof. Liang Chen (National 
Institute of Biological Sciences, Beijing, China). CAG pro-
moter is a strong promoter to mimic the high expression 
of EGFR-19 exon deletion mutation.18 Rosa26 promoter is 
weak-to-medium promoter to mimic the low expression of 
EGFR-19 exon deletion mutation.19 Beas-2B-EGFR-L858R 
is a cell line with EGFR-L858R expression inducible by 
doxycycline.20 Recombinant lentivirus expressing either vec-
tor (pEZ-Lv203) or pEZ-Lv203 subcloned with PD-L1 was 
constructed by FulenGen Corporation (Guangzhou, China). 
The gene sequence of PD-L1 was confirmed by polymerase 
chain reaction (PCR) sequencing. The plasmid DNA was 
transfected into Beas-2B cell line by using Lipofectamine 
LTX & PLUS_Reagent (Invitrogen, Carlsbad, CA) accord-
ing to the manufacturer’s instructions. Pooled Beas-2B cell 
populations expressing either pEZ-Lv203 or pEZ-Lv203-
PD-L1 were selected with 1 μg/ml of puromycin (Sigma-
Aldrich, St. Louis, MO). All the cell lines were cultured in 
DMEM supplemented with 10% fetal bovine serum and anti-
biotics (10,000 U/ml penicillin and 10 μg/ml streptomycin). 
All cells were maintained in a humidified incubator at 37°C 
with 5% carbon dioxide.
Western Blot Analysis
Cells were harvested and suspended in RIPA lysis buf-
fer (Thermo, Hercules, CA) containing a protease inhibitor 
cocktail (Sigma–Aldrich Corporation, St Louis, MO) and 
phosphatase inhibitor cocktail PhosSTOP (Roche, Mannheim, 
Germany). After incubation on ice for 30 minutes, cell lysate 
was centrifuged at 13,000 rpm for 20 minutes at 4°C. The 
protein content of the supernatant was determined using the 
Thermo Protein Assay Reagent (Thermo, Hercules, CA). Total 
of 30–60 μg protein per well was separated by 10% sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis and 
transferred to polyvinylidene difluoride membranes (Bio-Rad 
Laboratories, Hercules, CA). The membranes were immunob-
lotted with primary antibodies against PD-L1 (E1L3N™), 
EGF Receptor (D38BI), phospho-EGFR (Tyr1068), glyceral-
dehyde 3-phosphate dehydrogenase, phospho-p44/42MAPK 
(ERK1⁄2) (Thr202⁄Tyr204), p44/42 MAPK (ERK1/2), 
phospho-c-Jun, phospho-Akt (Ser473), AKT, and phospho-
S6 Ribosomal Protein (Ser235/236) over night at 4°C. All 
the above-mentioned antibodies were from Cell Signaling 
Technology (Danvers, MA). After three times washing, the 
membrane was further incubated with horseradish peroxidase-
conjugated donkey anti-rabbit secondary antibodies (1:2000, 
Santa Cruz, CA) at room temperature for 2 hours. Signals 
were detected by super signal West Dura Luminol/Enhancer 
solution (Thermo, Hercules, CA).
RNA Extraction and PCR
To quantify PD-L1 mRNA expression, total RNA was 
extracted from cells with TRIzol reagent (Invitrogen), and 
cDNA was synthesized using TaqMan MultiScribe Reverse 
Transcriptase (Applied Biosystems, Foster City, CA) accord-
ing to the manufacturer’s instructions. Quantitative real-
time PCR (RT-PCR) analysis was performed using an ABI 
Prism 7900-HT Sequence Detection System (96-well, 
Applied Biosystems). For RT-PCR, the following primers 
were used for the amplification of PD-L1, forward primer 
5′-CCTACTGGCATTTGCTGAACGCAT-3′ and reverse primer 
5′-ACCATAGCTGATCATGCAGCGGTA-3′. β-Actin: 5′-TCC 
TGTGGCATCCACGAAACT-3′ (forward) and 5′-GAAGCA 
TTTGCGGTGGACGAT-3′ (reverse). The experiments were 
triplicated. The relative expression of PD-L1 was normalized 
to β-actin expression. Different PD-L1 mRNA levels of other 
cell lines were relative to that of Beas-2B cells.
Immunofluorescence
Human A549, H1975, Beas-2B-CAG-EGFR-19del, and 
Beas-2B-CAG-vector cells grown on a chamber slide (BD 
Biosciences, San Jose, CA) were washed with cold phos-
phate-buffered saline (PBS), fixed with 4% paraformaldehyde 
in PBS for 15 minutes. After 1 hour blocking in PBS plus 
0.1% Tween-20 and 3% donkey serum, cells were incubated 
with primary antibodies of PD-L1 (E1L3N™, Cell Signaling 
Technology, Danvers, MA) at 4°C overnight. Then after three 
times washing, cells were incubated with secondary antibody 
(Alexa Fluor 488 or 555 donkey anti-rabbit IgG [H + L], 
Life Technologies, LA) for 1 hour at room temperature. After 
counterstaining with DAPI (P36931, Life technologies) for 5 
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minutes, slides were observed and photographed with fluores-
cence microscopy. These experiments were triplicated.
Surface Staining with Flow Cytometry
Attached cells (A549, H1975, Beas-2B-CAG-vector, 
Beas-2B-CAG-EGFR-19del, and Beas-2B-EGFR-L858R) 
were digested with 0.2% trypsin with 0.25% ethylenediami-
netetraacetic acid. Suspending cells (106) were fixed with 4% 
formaldehyde in PBS for 10 minutes. Cells were stained with 
the PD-L1 antibody (E1L3N™) or with the corresponding 
isotype control (Rabbit [DA1E] monoclonal antibody IgG, 
Cell Signaling Technology, Danvers, MA) for 1 hour at room 
temperature. Cells were washed twice with PBS by centrifuga-
tion and then stained with the anti-rabbit IgG (H + L), F(ab′)2 
Fragment (Alexa Fluor® 647 Conjugate, Life Technologies, 
LA) for 30 minutes. After washing, cells were analyzed by 
flow cytometry on a FACScan (BD Biosciences) instrument. 
Data analysis and graphical output were performed using 
FlowJo 7.6.1 software. These experiments were triplicated.
Stimulants and Inhibitors Treatment Assay
To study signaling pathways involved in PD-L1 regula-
tion mediated by EGFR, the following stimulants and inhibitors 
were used. Beas-2B cells were serum-starved for 2 hours then 
treated with 100 ng/ml EGF (recombinant human epidermal 
growth factor, cyt-217, PROSPEC Corporation, CA) for 30 
minutes, 24 or 48 hours. Cells were harvested for western blot 
analysis. The following kinase inhibitors were added to the cell 
cultures for 72 hours to suppress cellular protein kinase signal-
ing: EGFR tyrosine kinase inhibitors (gefitinib or CO-1686), 
ERK1/2 inhibitor (SCH772984), and AKT1/2/3inhibitor (MK-
2206 2HCL), which were all purchased from Selleckchem 
(Shanghai, China). Recombinant-humanized anti-PD-1 anti-
body (SHR-1210, P30121014061711) was provided by Shang 
Hai Heng Rui Pharmaceutical Corporation (Shanghai, China).
Beas-2B Cells or NSCLC Cells Cocultured  
with PBMCs
Beas-2B-PD-L1, Beas-2B-vecter, Beas-2B-CAG-
EGFR-19del, Beas-2B-CAG-vector, HCC827 and H1975 
cells were seeded into 24-well plates at a density of 3 × 104 
cells/well overnight. Human peripheral blood mononuclear 
cells (PBMCs) were isolated by Ficoll Paque density centrifu-
gation from peripheral blood donated by healthy volunteers. 
Then, the acquired PBMCs were added into coculture sys-
tem at a PBMC/attached objective cells ratio of 2:1. PBMC/
Beas-2B-PD-L1 cocultured cells were treated with anti-
PD-1 antibody (50 ng/ml) or vehicle. PBMC/Beas-2B-CAG-
EGFR-19del cocultured cells and PBMC/HCC827 cocultured 
cells were treated with anti-PD-1 antibody (50 ng/ml), gefi-
tinib (200 nM), or vehicle. PBMC/H1975 cocultured cells 
were treated with anti-PD-1 antibody (50 ng/ml), gefitinib 
(200 nM), CO-1686(200 nM), or vehicle. After 72 hour treat-
ment, PBMCs were harvested from the coculture system and 
stained with anti-human CD3 monoclonal antibody OKT-3, 
11–0037 (Affymetrix eBioscience, San Diego, CA) for apop-
tosis assay. The cell-free supernatant from cocultured system 
after 14,000 rpm centrifugation was collected for interferon 
(IFN)-γ analysis by enzyme-linked immunosorbent assay 
(ELISA).
Annexin V-APC/7-AAD Apoptosis Assay
CD3 positive T lymphocytes were sorted from PBMC 
after stained with CD3 antibody by flow cytometry. The apop-
tosis of CD3 positive T cells was determined according to the 
protocol of the Annexin V-APC/7-AAD Apoptosis Detection 
kit (KGA1023-1026, KeyGEN, Nanjing, China). The Annexin 
V-APC and 7-AAD fluorescence levels were measured by flow 
cytometry (BD Biosciences, FACS Calibur). The Annexin 
V-APC-positive cells (both 7-AAD-negative and 7-AAD--
positive) were defined as apoptotic cells.
IFN-γ Analysis by ELISA
Peripheral blood from 20 consecutive EGFR mutation 
NSCLC patients before and after EGFR-TKIs treatment for 1 
month was obtained in Sun Yat-Sen University Cancer Center 
(Guangzhou, China) from April 3, 2014 to June 1, 2014. Serum 
was isolated by centrifuging at 2000 rpm for 10 minutes. IFN-γ 
level in serum and cell-free supernatant was determined using 
ELISA kit Bio-Plex Pro (Bio-Rad Laboratories) according to 
the manufacturer’s protocol. The patients-related study pro-
tocol was approved by the Institutional Review Board of Sun 
Yat-Sen University Cancer Center (Guangzhou, China) and 
was conducted in accordance with the Declaration of Helsinki 
and good clinical practice. All the patients had provided writ-
ten informed consent before samples were collected.
Cell Viability Analysis
HCC827 and H1975 cells were seeded into 96-well 
plates at a density of 2.5 × 103 cells/well and incubated for 
overnight. Then HCC827 and H1975 cells were cocultured 
with PBMCs acquired previously. HCC827 and PBMC cocul-
tured cells were exposed to mock, AKT inhibitor (MK-2206 
2HCL; 2.0 μM), ERK1/2 inhibitor (SCH772984; 2.0 μM), 
gefitinib (0.2 μM), anti-PD-1 antibody, or gefitinib (0.2 μM) 
plus anti-PD-1 antibody (50 ng/ml). H1975 and PBMC cocul-
tured cells were exposed to mock, AKT inhibitor (MK-2206 
2HCL; 2.0 μM), ERK1/2 inhibitor (SCH772984; 2.0 μM), 
gefitinib (0.2 μM), CO-1686 (0.2 μM), anti-PD-1 antibody 
(50 ng/ml), or CO-1686 (0.2 μM) plus anti-PD-1 antibody 
(50 ng/ml). After 72 hours treatment, we removed the cul-
ture supernatant including suspended PBMCs and tumors 
cells, and then washed the attached tumors cells with culture 
medium for three times. The viability of residual HCC827 or 
H1975 cells was tested with CCK8 kit (Cell Counting Kit-8, 
Dojindo Co., Japan) according to the manufacturer’s protocol. 
The viability of vehicle group was normalized to 100%. Cell 
survival rate (%) = (OD value of treatment group/OD value 
of vehicle group) × 100%. All experiments were performed 
in triplicate.
Statistical Analysis
Representative results from three independent experi-
ments were shown in the present study. Numerical data were 
presented as the mean ± standard deviation of the mean (SD). 
Copyright © 2014 by the International Association for the Study of Lung Cancer
913Copyright © 2015 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 6, June 2015 Upregulation of PD-L1 by EGFR in EGFR-Driven NSCLC
The p-values between two experimental groups were tested 
by two-tailed Student’s t test and p-values less than 0.05 were 
considered significant.
RESULTS
Expression of PD-L1 in NSCLC Cell Lines Is 
Associated with EGFR Mutational Status
Western blot and RT-PCR were performed to detect the 
protein and mRNA level of several common human NSCLC 
cell lines. We found that the protein level of PD-L1 in EGFR-
mutant NSCLC cell lines (PC-9, HCC827, and H1975) was 
significantly higher than that in EGFR-wild type cell lines 
(A549 and H1993) and an immortalized human lung bron-
chial epithelial cell line (Beas-2B cell; Fig. 1A), which was 
consistent with the results of PD-L1 mRNA level (Fig. 1B). 
Moreover, we employed immunofluorescence to locate PD-L1 
in H1975 cell line (relatively higher PD-L1 expression) and 
A549 cell line (undetectable PD-L1 expression). Both cell 
membrane and cytoplasm in H1975 cell showed strong PD-L1 
signal (red fluorescence; Fig. 1C). The different levels of 
PD-L1 expression in A549 and H1975 were further confirmed 
by flow cytometry (Fig. 1D).
EGFR Activated by EGF Stimulation, 
Exon-19 Deletions, and L858R Mutation 
Induced PD-L1 Expression
Three types of EGFR activation were employed to 
investigate their association with PD-L1 expression. First, we 
used EGF as a ligand of EGFR to activate wild type EGFR, 
we found p-EGFR and PD-L1 protein levels were increased 
with dose escalation of EGF stimulation from 0 to 40 ng/ml in 
Beas-2B cells (Fig. 2A). Furthermore, we treated Beas-2B cell 
with 40 ng/ml EGF for 30 minutes, 24 and 48 hours, we found 
the PD-L1 protein expression was upregulated after the acti-
vation of EGFR by EGF treatment after 30 minutes, and the 
upregulation of PD-L1 was maintained for more than 48 hours 
even after p-EGFR recovered to control level (Fig. 2B). Next, 
we employed two plasmids with the lower and higher promoter 
activity to express different level EGFR with exon-19 dele-
tion. We found that the expression of PD-L1 was induced at a 
dose-dependent manner after an increasing level of p-EGFR 
(Fig. 2C). Furthermore, we used a plasmid that could express 
different levels of EGFR with L858R mutation after doxycy-
cline treatment. Fig. 2D shows that the expression of EGFR-
L858R mutation was induced by 2 μg/ml doxycycline for 0, 
FIGURE 1.  Programmed death-ligand 1 (PD-L1) expression was associated with epidermal growth factor receptor (EGFR) 
mutational status in human non–small-cell lung cancer (NSCLC) cell lines. A, The protein expression level of PD-L1 (detected 
by western blot) in several common NSCLC cell lines and an immortalized human lung bronchial epithelial cell line (Beas-2B). 
Glyceraldehyde 3-phosphate dehydrogenase was used to verify equal loading. B, The relative expression level of PD-L1 mRNA 
(detected by real-time polymerase chain reaction) in different NSCLC cell lines and Beas-2B as described above. The relative 
expression level of PD-L1 mRNA was normalized to that in Beas-2B cell line. C, The localization of PD-L1 (red signal) in H1975 
and A549 cell lines shown by immunofluorescence counterstained with DAPI (blue signal). D Flow cytometric analysis of cell-
surface PD-L1 expression in A549 and H1975 cell lines (PD-L1, red line; isotype controls, gray zone). All experiments were 
repeated three times. Representative data are shown.
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FIGURE 2.  Epidermal growth factor receptor (EGFR) activated by EGF stimulation, exon-19 deletions, and L858R mutation 
induced programmed death-ligand 1 (PD-L1) expression. A, The protein expression level of PD-L1 and p-EGFR (detected by 
western blot) in Beas-2B treated with different concentrations of EGF (0, 10, 20, and 40 ng/ml) for 30 minutes. B, The protein 
expression level of PD-L1 and p-EGFR (detected by western blot) in Beas-2B treated with EGF (40 ng/ml) for 30 minutes, 24 
hours, and 48 hours. C, The protein expression level of PD-L1, EGFR, and p-EGFR in Beas-2B cell, which was stably transfected 
with CAG vector plasmid as control, with Rosa-EGFR-19del and CAG-EGFR-19del plasmid to mimic the low and high expression 
of EGFR-19del, respectively. D, The protein expression level of PD-L1, EGFR, and p-EGFR in Beas-2B cell, which was induced by 
doxycycline (2 μg/ml) for 0, 3, 6, and 12 hours. E, The different levels of PD-L1 expression in Beas-2B-CAG-EGFR-19del, Beas-
2B-CAG-vector, and isotype control were further confirmed by flow cytometry. F, The expression of PD-L1 is detected by flow 
cytometry in the Beas-2B-EGFR-L858R cells induced by doxycycline (2 μg/ml) or not for 12 hours. G, The localization of PD-L1 
(red signal) and p-EGFR (green signal) in Beas-2B-CAG-EGFR-19del and Beas-2B-CAG-vector cell lines was shown by immuno-
fluorescence counterstained with DAPI (blue signal). Representative data of three independent experiments are shown.
Copyright © 2014 by the International Association for the Study of Lung Cancer
915Copyright © 2015 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 6, June 2015 Upregulation of PD-L1 by EGFR in EGFR-Driven NSCLC
3, 6, and 12 hours, which induced the increasing protein level 
of p-EGFR and PD-L1. The induction of PD-L1 by activated 
EGFR through two different types of mutant EGFR over-
expression was further confirmed by flow cytometry (Fig. 2E 
and F). Finally, we employed immunofluorescence to show 
the association between p-EGFR and PD-L1 expression. The 
higher expression of p-EGFR and PD-L1 was both presented 
on the membrane of Beas-2B cells with EGFR-19del over-
expression (Fig. 2G). Taken together, our results solidly indi-
cate that different manners of EGFR activation could induce 
PD-L1 expression.
Inhibiting EGFR Activation Could 
Reduce PD-L1 Expression
Because PD-L1 was induced by activated EGFR, it was 
implied that PD-L1 expression could be suppressed by EGFR-
TKIs. Gefitinib is the first generation EGFR-TKI that can tar-
get EGFR-19del and EGFR-L858R mutation. As shown in 
Figure 3A, gefitinib could reverse the upregulation of p-EGFR 
and PD-L1, which was induced by EGF stimulation at 48 and 
72 hour. In addition, gefitinib could also reverse the upreg-
ulation of PD-L1 mediated by EGFR-L858R in Beas-2B-
EGFR-L858R cells (Fig. 3B). EGFR activity was inhibited by 
different concentrations of gefitinib, and the protein expression 
of PD-L1 was decreased accordingly in PC-9 and HCC827 
cell lines, which are both NSCLC cell lines with EGFR-19del 
mutation (Fig. 3C and D). Then, H1975 cells harboring EGFR 
T790M mutation that is resistant to gefitinib was treated with 
gefitinib and CO-1686. As expected, p-EGFR was not altered 
in H1975 cells treated with gefitinib. The PD-L1 expression 
of H1975 cell line was not changed due to unaltered EGFR 
activity after gefitinib treatment. CO-1686 is a third genera-
tion EGFR-TKI that was reported to inhibit the activation of 
EGFR-T790M21. We found CO-1686 significantly inhibited 
the activation of EGFR and downregulated PD-L1 protein 
level. (Fig. 3E). Taken together, our data clearly showed that 
inhibiting EGFR activation could reduce PD-L1 expression in 
NSCLC with activated EGFR.
Activated EGFR Regulated PD-L1 Through 
ERK1/2/c-Jun but not AKT Pathway
To understand which signaling pathways are involved 
in EGFR-induced PD-L1 expression in NSCLC, we first 
assessed the downstream signaling pathways activated by 
EGFR. As expected, the p-ERK1/2 and p-AKT were activated 
by mutant EGFR and inhibited by gefitinib (Fig. 4A and B). 
Furthermore, to clarify the potential mechanisms of PD-L1 
upregulation by activated EGFR, we used the inhibitors of 
ERK1/2 or AKT1/2/3 to block the downstream pathways of 
EGFR in Beas-2B-CAG-EGFR-19del cells with exogenous 
expression of EGFR-19del and in HCC827 cells with endog-
enous expression of EGFR-19del. We found ERK1/2 inhibitor 
FIGURE 3.  Inhibiting epidermal growth factor receptor (EGFR) activation could reduce programmed death-ligand 1 (PD-L1) 
expression. A, The protein expression level of PD-L1 and p-EGFR in Beas-2B cells, which were treated with EGF alone or EGF 
(40 ng/ml) plus gefitinib (0.5 μM), was detected by western blot at the time of 48 and 72 hours. EGF (40 ng/ml) was added 
once every 12 hours. B, The protein expression level of PD-L1 and p-EGFR in Beas-2B-L858R cells, which were treated with 
doxycycline (2 μg/ml) alone or doxycycline (2 μg/ml) plus gefitinib (0.5 μM), was detected by western blot at the time of 48 
and 72 hours. C and D, The protein expression alteration of PD-L1 and p-EGFR in HCC827 or PC-9 cell lines was determined 
after gefitinib treatment in concentrations indicated for 72 hours. E, The protein expression alteration of PD-L1 and p-EGFR was 
tested in H1975 cell treated with 0.2 μM gefitinib or 0.2 μM CO-1686 for 72 hours. Representative results from three indepen-
dent experiments are shown.
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(SCH772984) could effectively inhibit the p-ERK1/2 and 
p-c-Jun induced by EGFR-19del, which further resulted in 
the decrease of PD-L1 expression (Fig. 4C and E). In addi-
tion, AKT1/2/3 inhibitor (MK-2206 2HCL) could effectively 
suppress p-AKT1/2/3 and p-S6 in a dose-dependent manner, 
but the expression of PD-L1 was not altered (Fig. 4D and F). 
To clarify whether ERK1/2-regulated PD-L1 is dependent 
on signaling pathway mechanism, we tested the viability of 
HCC827 and Beas-2B-EGFR-19del cells treated with ERK1/2 
inhibitor or AKT inhibitor. We found both ERK1/2 inhibitor 
and AKT inhibitor similarly and weakly inhibited the viability 
of HCC827 and Beas-2B-EGFR-19del cells (Supplementary 
Figure 1, Supplemental Digital Content 1, http://links.lww.
com/JTO/A808). Thus, the data showed the regulation of 
PD-L1 by ERK1/2 but not AKT pathway was through the 
mechanism of specific signaling pathway. Taken together, these 
results show that activated EGFR induced PD-L1 expression 
through p-ERK1/2/p-c-Jun signaling pathways rather than 
p-AKT/p-S6 pathway in NSCLC cells with mutant EGFR.
Upregulation of PD-L1 Mediated by EGFR 
Activation Could Induced the Apoptosis 
of T Cells Through PD-L1/PD-1 Axis
It is well known that PD-L1 in tumor cell could lead to 
apoptosis or anergy of T cells. First, we constructed stable cell 
line with PD-L1 over-expression (Beas-2B-PD-L1; Fig. 5A). 
Human PBMCs were isolated by Ficoll Paque density centrifu-
gation from peripheral blood donated by healthy volunteers. 
Then, the PBMCs were added to coculture system with Beas-
2B-PD-L1 or Beas-2B-vector stable cell lines at the ratio of 2:1. 
FIGURE 4.  Activated epidermal 
growth factor receptor (EGFR) regu-
lated programmed death-ligand 1 
(PD-L1) through ERK1/2 pathways 
but not AKT. A, The protein expres-
sion level of p-EGFR, p-AKT, AKT, 
p-ERK1/2, ERK1/2 in Beas-2B-CAG-
vector, Beas-2B-Rosa-EGFR-19del, and 
Beas-2B-CAG-EGFR-19del cell lines. B, 
The protein expression level of p-EGFR, 
p-AKT, AKT, p-ERK1/2, and ERK1/2 in 
HCC827 cell treated with 0, 0.5, and 
1.0 μM gefitinib for 72 hours. C, The 
protein expression level of p-ERK1/2, 
ERK1/2, p-c-Jun, and PD-L1 in Beas-
2B-CAG-vector cells and Beas-2B-CAG-
EGFR-19del cells, which were treated 
with 0, 0.5, and 1.0 μM ERK1/2 
inhibitor (SCH772984) for 72 hours. D, 
The protein expression level of p-AKT, 
AKT, p-S6, and PD-L1 in Beas-2B-CAG-
vector cells and Beas-2B-CAG-EGFR-
19del cells, which were treated with 
0, 1.0, and 2.0 μM AKT1/2/3 inhibitor 
(MK-2206 2HCL) for 72 hours. E, The 
protein expression level of p-ERK1/2, 
ERK1/2, p-c-Jun, and PD-L1 in HCC827 
cells, which were treated with 0, 0.5, 
1.0, and 2.0 μM ERK1/2 inhibitor for 
72 hours. F, The protein expression 
level of p-AKT, AKT, p-S6, and PD-L1 
in HCC827 cells, which were treated 
with 0, 0.5, 1.0, and 2.0 μM AKT1/2/3 
inhibitor for 72 hours. Representative 
results from three independent experi-
ments are shown.
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We found the apoptosis rate of CD3+ T cells was higher when 
cocultured with Beas-2B-PD-L1 cells than that with Beas-2B-
PD-L1-vecter control (42.3 ± 2.5 vs. 7.2 ± 1.4%, p < 0.0001), 
and anti-PD-1 antibody significantly reduced the apoptosis rate 
of T cells to 12.1 ± 1.3% (p < 0.0001; Fig. 5C and D). This 
result demonstrated that anti-PD-1 antibody could reverse the 
apoptosis of T cells induced by PD-L1. To investigate whether 
PD-L1 upregulation mediated by EGFR activation could also 
affect T cells function, we cocultured PBMC with Beas-2B-
CAG-EGFR-19del cells or Beas-2B-CAG-vector cells. As 
Figure 5B shows, Beas-2B-CAG-EGFR-19del cells expressed 
higher PD-L1 than Beas-2B-CAG-vector cells. The apoptosis 
rate of CD3+ T cells cocultured with Beas-2B-CAG-EGFR-
19del cells was higher than that with Beas-2B-CAG-vector 
cells (38.6 ± 3.5 vs. 13.2 ± 1.1%, p = 0.0004). Similarly, block-
ing PD-1 with anti-PD-1 antibody in Beas-2B-EGFR-19del/
PBMC coculture system reduced the apoptosis rate of T cells 
to 14.2 ± 1.0% (p = 0.0005). In addition, we used gefitinib to 
reduce the expression of PD-L1 mediated by EGFR activa-
tion. We found that the apoptosis rate of T cells decreased to 
19.8 ± 2.4% (p = 0.0027; Fig. 5E and F). Thus, our results show 
that PD-L1 upregulation mediated by EGFR activation could 
induce the apoptosis of T cells through PD-L1/PD-1 axis.
Inhibiting EGFR by EGFR-TKIs Could 
Reverse the Apoptosis of T cells and 
Enhance the Production of IFN-γ
To determine whether inhibiting mutant EGFR by 
EGFR-TKIs could reverse the apoptosis of T cells, firstly 
we tested the effects of EGFR-TKIs on T cells, we found 
that nanomole EGFR-TKIs could not influence the viability 
of T cells (Supplementary Figure 2, Supplemental Digital 
FIGURE 5.  Programmed death-ligand 1 (PD-L1) mediated by EGFR activation could induced the apoptosis of T cells through 
PD-L1/PD-1 axis. A, The protein expression level of PD-L1 in Beas-2B-PD-L1 and Beas-2B-PD-L1-vecter was detected by western 
blot. B, The protein expression level of p-EGFR and PD-L1 in Beas-2B-CAG-vector and Beas-2B-CAG-EGFR-19del was detected by 
western blot. C and D, The apoptosis rates of T cell cocultured with Beas-2B-PD-L1-vecter cells and Beas-2B-PD-L1 cells, which 
were treated with mock or anti-PD-1 antibody (50 ng/ml), were detected by Annexin V-APC/7-AAD apoptosis assay. E and F, 
The apoptosis rates of T cell cocultured with Beas-2B-CAG-vector cell and Beas-CAG-EGFR-19del, which were treated with mock 
or anti-PD-1 antibody (50 ng/ml) or gefitinib (0.2 μM), were detected by Annexin V-APC/7-AAD apoptosis assay. The Annexin 
V-APC-positive cells (both 7-AAD-negative and 7-AAD-positive) were defined as apoptotic cells. Representative results from three 
independent experiments are shown. **, p < 0.001; ***, p < 0.0001.
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Content 2, http://links.lww.com/JTO/A809). So we thought 
that the EGFR-TKIs might not directly influence T cells in the 
tumor microenvironment. Then, we cocultured PBMC with 
HCC827 or H1975 cells and found the apoptosis rate of T 
cells decreased from 37.5 ± 1.5% to 17.1 ± 1.6% (p < 0.0001) 
in HCC827/PBMC cocultured system, but not in H1975/
PBMC cocultured system when treated with gefitinib (Fig. 
6A, B, and D). However, CO-1686 decreased the apoptosis 
rate of T cells from 32.6 ± 1.3% to 18.8 ± 1.0% (p < 0.0001) in 
H1975/PBMC cocultured system (Fig. 6C and D). Blockade 
of PD-1 could reverse the apoptosis of T cells cocultured with 
both HCC827 and H1975 cells (p < 0.0001; Fig. 6B and D).
To understand whether EGFR-TKIs could affect the 
immune function of T cells when they were cocultured with 
EGFR mutant NSCLC cells. The cocultured supernatant was 
collected for IFN-γ measurement. We found IFN-γ was mark-
edly increased in the supernatant of HCC827/PBMC coculture 
system after gefitinib treatment (Fig. 6E). As expected, gefi-
tinib did not affect the IFN-γ level but CO-1686 obviously 
enhanced the production of IFN-γ in the supernatant of H1975/
FIGURE 6.  Inhibiting epidermal growth factor receptor (EGFR) by EGFR-tyrosine kinase inhibitors (TKIs) could reverse the 
apoptosis of T cells and enhance the production of interferon (IFN)-γ. A and B, The apoptosis rates of T cells cocultured with 
HCC827, which were treated with mock or gefitinib (0.2 μM) or anti-programmed death 1 (PD-1) antibody (50 ng/ml), were 
detected by Annexin V-APC/7-AAD apoptosis assay. C and D, The apoptosis rates of T cells cocultured with H1975, which were 
treated with mock or gefitinib (0.2 μM) or CO-1686 (0.2 μM) or anti-PD-1 antibody (50 ng/ml). E, The level of IFN-γ from the 
supernatants of HCC827 and T cell coculture system was detected by enzyme-linked immunosorbent assay (ELISA) after treat-
ment with gefitinib (0.2 μM) or mock. F, The level of IFN-γ from the supernatants of H1975 cell and T cell coculture system 
was detected by ELISA after treatment with gefitinib (0.2 μM) or CO-1686 (0.2 μM) or mock. G, The serum IFN-γ level from 
20 non–small-cell lung cancer patients treated with EGFR-TKIs at 1 month and baseline were detected by ELISA. Representative 
results from three independent experiments are shown. ***, p < 0.0001.
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PBMC coculture system (Fig. 6F). These results indicate that 
inhibiting EGFR by EGFR-TKIs could reverse the apoptosis of 
T cells and enhance the production of IFN-γ in vitro.
Besides, we analyzed the serum IFN-γ level from 20 
NSCLC patients who received gefitinib or erlotinib. The 
serum IFN-γ level from patients after 1-month gefitinib or 
erlotinib treatment was significantly higher than that at base-
line (p = 0.0167). It indicated that EGFR-TKIs might also 
enhance the immune function of T cells in NSCLC patients 
with EGFR mutation (Fig. 6G).
Blockade of PD-1 Could Suppress 
the Viability of EGFR-TKI Sensitive 
and Resistant NSCLC Cells
Our above data showed that blockade of PD-1 or inhib-
iting EGFR by sensitive EGFR-TKIs could reverse the sup-
pression of T cells’ function. To determine the effect of PD-1 
blocking or EGFR-TKIs on tumor cells in PBMC and tumor 
cells coculture system, we tested the viability of attached 
tumor cells. Tumor cells cocultured with PBMC were treated 
with ERK1/2 inhibitor, AKT inhibitor, EGFR-TKIs, anti-PD-1 
antibody, or EGFR-TKIs plus anti-PD-1 antibody. After 72 
hours treatment, we removed the culture supernatant includ-
ing suspended PBMCs and tumors cells and then washed the 
attached tumors cells with culture medium for three times. 
Then the viability of attached tumors cells was tested with 
CCK8 kit. We found blockade of PD-1 decreased the viability 
of HCC827 cells to 67.90 ± 2.39% (p < 0.0001) and decreased 
the viability of gefitinib resistant H1975 cells to 67.23 ± 4.59% 
(p = 0.0003). Because A549 has quite low PD-L1 expression, 
we chose A549 cell line as a control to compare HCC827 with 
A549 cells for the anti-PD-1 treatments in the coculture sys-
tem. We found the anti-PD-1 treatment had weaker effects on 
killing cancer cells in coculture system with A549 cells than 
with HCC827 cells (Supplementary Figure 3, Supplemental 
Digital Content 3, http://links.lww.com/JTO/A810). As 
shown in Figure 7, the survival rates of HCC827 cells fell to 
38.87 ± 2.60% after gefitinib administration. However, the via-
bility of H1975 cells exposed to gefitinib was not changed. As 
expected, CO-1686 significantly decreased the survival rate of 
H1975 cells to 37.81 ± 2.48% (p < 0.0001).
Then, we tried to explore whether EGFR-TKIs plus anti-
PD-1 antibody could have additional inhibition on tumor cells 
in the coculture system. No synergistic tumor killing effect of 
EGFR-TKI and anti-PD-1 antibody in vitro coculture system 
was observed (Fig. 7A and B).
Furthermore, to compare the effects of core downstream 
signaling pathways (ERK1/2 and AKT) with anti-PD-1 anti-
body, EGFR TKI, or both treatments, we tested the effects of 
ERK1/2 and AKT inhibitors on both EGFR-TKIs sensitive 
HCC827 cells and EGFR-TKIs resistant H1975 cells in the 
cocultured system. We found that ERK1/2 inhibitor decreased 
the survival rates of HCC827 and H1975 cells to 78.95 ± 2.17% 
(p < 0.001) and 82.28 ± 3.29% (p < 0.001), respectively, in 
the coculture system. Moreover, ERK1/2 inhibitors had stron-
ger cancer cells killing effects compared with AKT inhibi-
tors (Fig. 7). Taken together, these results demonstrated that 
anti-PD-1 antibody or EGFR-TKIs or ERK1/2 inhibitor could 
activate the antitumor immunity of T cells and decrease the 
survival rates of EGFR-TKI sensitive and resistant NSCLC 
cells with EGFR mutation in tumors cells and PBMC cocul-
ture system.
FIGURE 7.  Blockade of programmed death 1 (PD-1) could suppress the viability of epidermal growth factor receptor tyrosine 
kinase inhibitors (EGFR-TKI) sensitive and resistant non–small-cell lung cancer (NSCLC) cells. A, The survival rates of HCC827 
cells cocultured with peripheral blood mononuclear cells (PBMC) were measured after treatment with mock, AKT inhibitor (2.0 
μM), ERK1/2 inhibitor (2.0 μM), gefitinib (0.2 μM), anti-PD-1 antibody (50 ng/ml), or gefitinib (0.2 μM) plus anti-PD-1 anti-
body (50 ng/ml) for 72 hours. B, The survival rates of H1975 cells cocultured with PBMCs were measured after treatment with 
mock, AKT inhibitor (2.0 μM), ERK1/2 inhibitor (2.0 μM), gefitinib (0.2 μM), CO-1686 (0.2 μM), anti-PD-1 antibody (50 ng/ml), 
or CO-1686(0.2 μM) plus anti-PD-1 antibody (50 ng/ml) for 72 hours. Representative results from three independent experi-
ments are shown. **, p < 0.001; ***, p < 0.0001.
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DISCUSSION
Recently, it was reported that EGFR mutational sta-
tus was associated with PD-L1 expression.15,16 However, 
the molecular mechanisms of PD-L1 mediated by EGFR in 
NSCLC and the potential clinical significance of blocking 
PD-1/PD-L1 in EGFR-TKIs sensitive and EGFR-TKIs resis-
tant NSCLC with EGFR mutation are unclear.
In the present study, we demonstrated that the expression 
of PD-L1 in EGFR-mutant NSCLC cell lines was higher than 
that in cell lines with wild-type EGFR. We further found that 
three models of EGFR activation including EGF stimulation, 
EGFR-19del, and EGFR-L858R mutation could induce PD-L1 
expression, indicating that constitutive oncogene pathway acti-
vation could upregulate PD-L1. It was previously reported that 
FIGURE 8.  Molecular regulatory mechanism of programmed death-ligand 1 (PD-L1) by epidermal growth factor recep-
tor (EGFR) in non–small-cell lung cancer (NSCLC) and proposed optional treatment strategies for EGFR mutant NSCLC. A, 
p-ERK1/2/p-c-Jun but not p-AKT/p-S6 pathway plays a critical role in remodeling the expression of PD-L1 by EGFR activation. 
EGFR-tyrosine kinase inhibitors (TKIs) could reverse the immune suppression by downregulating PD-L1. (B) Proposed treatment 
paradigms for EGFR-TKI sensitive and resistant NSCLC with EGFR mutation.
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over-expression of mutant EGFR but not K-ras could increase 
the level of PD-L1 mRNA in Beas-2B cells.15 This shows that 
PD-L1 upregulation is induced by EGFR activation and not 
simply by oncogenic stress. This phenomenon has extensively 
reported in other tumor types as innate immune resistance.6,7 
Parsa et al. 22 found loss of phosphatase and tensin homolog, 
and the resulting activation of phosphatidylinositol-3-OH kinase 
pathway significantly elevated PD-L1 expression in glioma. 
Similarly, constitutive activation of nucleophosmin– anaplastic 
lymphoma kinase was reported to drive PD-L1 expression 
through signal transducer and activator of transcription-3 
(STAT3) in lymphoma.23 More recently, we found Epstein–Barr 
virus driven latent membrane protein 1 , a well-recognized initi-
ator of oncogene of Epstein–Barr virus-infected nasopharvngeal 
carcinoma participated in PD-L1 regulation.24 PD-L1 could be 
regulated not only by constitutive oncogene pathway activation 
but also by some inflammatory cytokines, such as IFN-γ.25 The 
present study focused on the mechanism of PD-L1 regulation by 
oncogene pathways. Here, our data solidly supported that onco-
gene EGFR driven PD-L1 expression represents an intrinsic 
regulation of PD-L1 in NSCLC with EGFR mutation.
To explore the molecular mechanism of PD-L1 upregu-
lation by EGFR activation, we tested the downstream path-
ways of EGFR. As previously reported, EGFR remarkably 
increased the activity of ERK1/2 and AKT, which are involved 
in the proliferation, antiapoptosis, and invasion of tumor 
cells.26,27 The upregulation of PD-L1 mediated by EGFR 
activation was associated with the activation of ERK1/2/c-
Jun and AKT/S6 pathways. By inhibiting p-ERK1/2, PD-L1 
decreased after p-ERK1/2/p-Jun downregulation in a clear 
dose-dependent manner. However, inhibiting p-AKT did not 
alter the expression of PD-L1. As shown in Figure 7, ERK1/2 
inhibitors had stronger cancer cells’ killing effects compared 
with AKT inhibitors in the coculture system of EGFR-TKIs 
sensitive HCC827 and EGFR-TKIs resistant H1975 cells. 
This could be further explained that inhibiting ERK1/2 path-
way but not AKT pathway could downregulate PD-L1 and 
enhance the T cell functions. All these results indicate that 
p-ERK1/2/p-c-Jun but not p-AKT/p-S6 pathway plays a criti-
cal role in remodeling the expression of PD-L1 by EGFR. 
P-ERK1/2/p-c-Jun pathway activation was also reported to 
mediate upregulation of PD-L1 in v-raf murine sarcoma viral 
oncogene homolog B (BRAF)-inhibitor-resistant myeloma.28
It has widely been reported that PD-L1 was an indicator 
of poorer survival in most advanced cancers.16,29–31 Whereas, 
recently, some studies found PD-L1 was a positive prognostic 
factor in some solid tumors.32,33 Recently, D’Incecco et al. found 
that PD-L1 confers favorable TTP in EGFR-mutant NSCLC 
patients treated with EGFR-TKIs. The discrepancy across dif-
ferent studies remains unclear but may be because of varia-
tions in IHC technique, cancer type, stage of cancer analyzed, 
and treatment history.24 Here, we found that inhibiting EGFR 
activation by EGFR-TKI could reduce PD-L1 expression and 
could reverse the suppression of T cells in the EGFR-TKI sen-
sitive NSCLC. IFN-γ, an indicator of T cell function, was also 
increased in the serum of EGFR mutant NSCLC patients after 
EGFR-TKIs treatment. Our study implies that EGFR mutant 
NSCLC patients may benefit not only from direct tumor 
killing effect of EGFR-TKIs but also indirectly from immune 
enhancement after EGFR-TKIs treatment. NSCLC patients 
with higher PD-L1 level might represent a subpopulation that 
could gain additional immune benefit from EGFR-TKIs and 
therefore achieve longer TTP after EGFR-TKIs treatment.
To explore the difference of anti-PD-1 treatment in the 
coculture system with high expression PD-L1 cell line and 
low expression-PD-L1 cell line, we chose A549 cell line as 
a control, given A549 cells has quite low PD-L1 expression. 
We found that the anti-PD-1 treatment had weaker effects on 
killing cancer cells in coculture system with A549 cells than 
with HCC827 cells (Supplementary Figure 3, Supplemental 
Digital Content 3, http://links.lww.com/JTO/A810). This 
may be because that A549 had relatively weak expression 
of PD-L1, and therefore, less effect of anti-PD1 treatment 
could be achieved. Although HCC827 expressed high level of 
PD-L1, it is easily interpreted that anti-PD1 antibody could 
significantly free the immune suppression of T cells and hence 
have more killing effects on cancer cells. Therefore, the higher 
PD-L1 expression might be related with the better efficacy of 
anti-PD-1 treatment.
Currently, although gefitinib and erlotinib are approved 
as the first-line treatment of EGFR-mutant NSCLC patients, 
a majority of them eventually develop secondary resistance to 
gefitinib and erlotinib. Novel treatment options for EGFR-TKIs 
resistance include CO-1686,34 AZD9291,35 and HM6171336 
for EGFR T790M and EGFR-TKIs plus c-met inhibitors for 
c-met amplification.37 However, the role of immunotherapy in 
EGFR-TKIs-resistant patients has not been revealed. Because 
we found the upregulation of PD-L1 by EGFR activation 
could mediate immune escape in EGFR-driven NSCLC, we 
analyzed the tumor inhibition by EGFR-TKIs, PD-1 block-
ing, or both. As expected, gefitinib had strong tumor inhibition 
in EGFR-TKI sensitive HCC827 cells, but not H1975 cells 
with EGFR-T790M mutation. CO1686, a third generation 
EGFR-TKIs could significantly inhibit the viability of H1975 
cells. Interestingly, the viability of both gefitinib sensitive 
and resistant cells was inhibited by blockade of PD-1. This 
implies that blockade of PD-1 or PD-L1 maybe a promising 
optional treatment for PD-L1 upregulated NSCLC patients 
with EGFR mutation, especially for EGFR-TKIs resistant 
NSCLC patients.
As we known, targeted therapy usually have rapid and 
impressive response rates but modest progression-free sur-
vival, whereas immunotherapy can achieve durable tumor 
control but associated with lower response rates. Combining 
targeted therapy with immune therapy is proposed and inves-
tigated in several ongoing clinical trials.38–41 In the present 
study, we did not observe the synergistic effect of EGFR-TKIs 
and anti-PD-1 antibody combination. It is probably because 
that the immune escape in EGFR-driven NSCLC is mainly 
mediated by the upregulation of PD-L1 through EGFR activa-
tion. EGFR-TKIs and anti-PD-1 antibody may therefore have 
similar but not additional effects on breaking the interaction 
of PD-1/PD-L1 in EGFR mutant NSCLC. The limitations of 
the present study need to be considered. This is an in vitro 
study, and PBMCs from healthy volunteers could not totally 
mirror infiltrated T cells in the tumor microenvironment. 
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Therefore, more well-designed in vivo studies are urgently 
required to explore whether there is synergistic effect of 
combining EGFR-TKIs and anti-PD-1/PD-L1 antibodies in 
EGFR mutant NSCLC and randomized clinical trials to com-
pare EGFR-TKIs with anti-PD-1/PD-L1 treatment are also 
urgently needed.
In summary, this is the first study to clarify the detailed 
mechanism of PD-L1 upregulation, which could be mediated 
by EGFR activation in NSCLC. Besides, we found that EGFR-
TKIs could not only directly inhibit tumor viability but also 
indirectly enhance antitumor immunity through the downreg-
ulation of PD-L1. We proposed that anti-PD-1 or anti-PD-L1 
antibodies maybe a promising treatment option for NSCLC 
with EGFR mutation, especially for those with EGFR-TKIs 
resistance. More evidence is needed to explore the feasibility 
of combining EGFR-TKIs and anti-PD-1/PD-L1 antibodies 
before this strategy could be translated into clinical practice.
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